NVO (Novo Nordisk AS) Total Current Assets : $29,050 Mil (As of Sep. 2024)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk AS Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Novo Nordisk AS's total current assets for the quarter that ended in Sep. 2024 was $29,050 Mil.

Novo Nordisk AS Total Current Assets Historical Data

The historical data trend for Novo Nordisk AS's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk AS Total Current Assets Chart

Novo Nordisk AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

9,290.04

10,761.19

13,006.38

15,405.89

20,431.62

Novo Nordisk AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Current Assets	Get a 7-Day Free Trial															20,349.90	20,431.62	16,971.49	25,599.98	29,050.31

Novo Nordisk AS Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Novo Nordisk AS's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	4422.953	+	11011.441	+	4654.269	+	342.952
	=	20,432

Novo Nordisk AS's Total Current Assets for the quarter that ended in Sep. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	11146.323	+	11853.081	+	5648.11	+	402.799
	=	29,050

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Novo Nordisk AS (NYSE:NVO) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Novo Nordisk AS's Liquidation Value for the quarter that ended in Sep. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	11146.323	-	41220.453	+	0.75 * 9868.86	+	0.5 * 5648.11
=	-19,848

Novo Nordisk AS Total Current Assets Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (NYSE:NVO) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico 0TDD:UK NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NOV:Bulgaria NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, 2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.